πŸ‡ΊπŸ‡Έ FDA
Patent

US 9868774

Anti-CD22 chimeric antigen receptors

granted A61KA61K38/00A61P

Quick answer

US patent 9868774 (Anti-CD22 chimeric antigen receptors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/00, A61P, A61P35/00, A61P35/02